News from im healthscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 01, 2020, 15:20 ET Acquisition of IM HealthScience Completed

IM HealthScience® (IMH), along with its sister company, Physician's Seal® (PS), have been acquired by Nestlé Health Science. The acquisition was...


Aug 10, 2020, 11:20 ET For The Sixth Year In A Row, In A Survey Of Gastroenterologists' Preferences For IBS Products, IBgard® Widens Its Already Preeminent "#1 Recommended"[1] Status

IM HealthScience®, innovators of medical foods and dietary supplements, today announced the results of a high-quality, nationwide survey conducted...


Aug 23, 2019, 07:03 ET U.S. Gastroenterologists Endorse Fiber Choice® Chewable Prebiotic Fiber Supplement With A "#1-Recommended" Rating[1]

IM HealthScience® (IMH), innovators of medical foods and dietary supplements, today announced that a high-quality, nationwide survey, conducted among ...


Aug 23, 2019, 07:02 ET For The Third Year In A Row, Gastroenterologists Nationwide Endorse Nonprescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion(i)) (ii)

IM HealthScience®, innovators of medical foods and dietary supplements, today announced that a high-quality, nationwide survey, conducted among a...


Aug 07, 2019, 23:40 ET In the Longest-Ever String of Yearly Surveys on Gastroenterologists' Preferences for Recommending Products for IBS, IBgard Continues to Widen its Already Pre-Eminent "#1 Recommended"(1) Status

IM HealthScience®, innovators of medical foods and dietary supplements, today announced the results of a high-quality, nationwide survey conducted...


Aug 07, 2019, 19:22 ET First-Ever 36 Month Real-World, Post-Marketing Surveillance Study Confirms The Excellent Safety And Tolerability Profile Of IBgard®, A Non-Prescription Product For IBS

IM HealthScience® (IMH) today announced favorable results from the longest-running post-marketing surveillance study of its type. This study called...


Apr 30, 2019, 21:29 ET Peer-Reviewed Medical Journal Publishes Landmark Study on Efficacy and Safety of FDgard® (COLM-SST), Demonstrating Rapid Reduction of Functional Dyspepsia (FD or Recurring, Meal-Triggered Indigestion) Symptoms Within 24 Hours

IM HealthScience today announced that Clinical and Translational Gastroenterology (CTG), a peer-reviewed medical journal, has published the U.S....


Nov 08, 2018, 09:03 ET For The Fourth Year In A Row, U.S. Gastroenterologists Endorse Clinically Studied, Nonprescription IBS Product, IBgard®, By An Overwhelming Margin

IM HealthScience®, innovators of patented nonprescription medical foods, revealed results of a nationwide survey conducted among gastroenterologists...


Oct 09, 2018, 15:21 ET American College Of Gastroenterology (ACG) 2018 IBS Monograph Reaffirms The Preceding ACG 2014 IBS Monograph's Support For Peppermint Oil's Use In IBS But Qualifies It With The Need For More Distal Delivery.

IM HealthScience® (IMH) today announced that the 2018 ACG Monograph on Management of Irritable Bowel Syndrome (published in June 2018) reaffirms the...


Oct 09, 2018, 15:11 ET Twenty-Four Month, Post-Marketing Safety Surveillance Data Presented At The American College Of Gastroenterology (ACG) Annual Meeting Further Confirms Favorable Safety And Tolerability Profile For IBgard®

IM HealthScience® (IMH), innovators of medical foods, today presented favorable, post-marketing safety surveillance data for IBgard®, a novel medical ...


Jul 03, 2018, 09:03 ET For The Second Year In A Row, Gastroenterologists Nationwide Endorse Non-Prescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion) [i]

IM HealthScience®, innovators of medical foods and dietary supplements, today announced a high-quality, nationwide survey conducted among a...


Jun 03, 2018, 08:03 ET Fiber Choice® Chewable Prebiotic Fiber Supplement Achieves #1-Recommended Status From Gastroenterologists Nationwide

IM HealthScience® (IMH), innovators of medical foods and dietary supplements, today announced a high-quality and replicated nationwide survey...


Apr 19, 2018, 01:18 ET Real-World Data From Surveillance Study Confirms Excellent Safety And Tolerability Profile Of IBgard® At 24 Months

IM HealthScience® (IMH) today announced favorable results from its Irritable Bowel Syndrome Safety Update at 24 Months (IBSSU-24), a real-world...


Nov 01, 2017, 09:03 ET U.S. Gastroenterologists Endorse Non-Prescription FDgard® For Functional Dyspepsia (Recurring Indigestion)

IM HealthScience®, innovators of FDgard®, a clinically studied, non-prescription medical food using a novel approach in the dietary management of...


Oct 30, 2017, 09:12 ET For The Third Year In A Row, U.S. Gastroenterologists Endorse Clinically Studied, Non-Prescription IBgard® For Irritable Bowel Syndrome (IBS), By Overwhelming Margin

IM HealthScience®, innovators of IBgard®, a clinically studied, non-prescription medical food using a novel approach in the dietary management of...


Oct 18, 2017, 08:00 ET Final Results Of Real-World Data From Observational Study Underscores High Levels Of Patient Satisfaction And Rapid Improvement Of Functional Dyspepsia (Recurring Indigestion) With Non-Prescription FDgard®

IM HealthScience® (IMH) today announced complete and final results of FDACT™ (Functional Dyspepsia Adherence and Compliance Trial), a real-world...


Sep 25, 2017, 09:02 ET Global, Peer-Reviewed Medical Journal Publishes Results Of A First-Ever Data Analysis In Irritable Bowel Syndrome (IBS) Patients With Mixed Diarrhea And Constipation (IBS-M), Demonstrating Effectiveness Of The Novel Delivery System Of Peppermint Oil In IBgard®

IM HealthScience® today announced that Internal Medicine Review, a global, peer-reviewed medical journal, has published the first-ever clinical data...


Aug 24, 2017, 09:32 ET Real-World Data From Surveillance Study At 12 Months Confirms Excellent Safety And Tolerability Profile Of New, Non-Prescription FDgard® For Functional Dyspepsia

IM HealthScience® (IMH) today announced favorable results from its Functional Dyspepsia Safety Update at 12 months (FDSU-12), a real-world,...


May 10, 2017, 10:30 ET Additional Data Analysis From An IBS (Irritable Bowel Syndrome) Clinical Trial Demonstrate IBgard® Delivered Unprecedented Symptom Reduction In The Largest And Most Dissatisfied Group Of IBS Patients

The more recent scientific understanding of Irritable Bowel Syndrome (IBS) having multiple causes, including reversible, low-grade inflammation,...


Apr 03, 2017, 09:37 ET Real-World Data From Surveillance Study Confirms Excellent Safety And Tolerability Profile Of New, Non-Prescription FDgard® For Functional Dyspepsia (Non-Heartburn Indigestion)

IM HealthScience® (IMH) today announced favorable results from its Functional Dyspepsia Safety Update at 6 months (FDSU-6), a real-world,...